Production of the Russian Smallpox Drug “NIOCH-14” May Start in the Spring of 2026
This is the first chemical drug in Russia intended for the treatment and emergency prevention of smallpox and other orthopoxvirus infections, including mpox.
R-Pharm Import-Substitutes German Erbitux — Drug for Head and Neck Cancer Therapy
The Ministry of Health of the Russian Federation has...
Petrovax Pharm Investments in Meningitis Vaccine Production Exceed 3 Billion Rubles
Biopharmaceutical company Petrovax Pharm has announced receiving an expanded...
Ellara Prepares to Launch Unique Peptide Synthesis Facility
Pharmaceutical company Ellara is completing preparations for the opening...
GMP Registry: New Certificates Issued and Refusals in January 2026
On January 26, the Ministry of Industry and Trade...
EU Approves the Most Extensive Pharmaceutical Legislation Reform in 20 Years
The European Parliament and the Council of the European...
Eli Lilly and Nvidia Launch LillyPod — The Most Powerful AI Supercomputer in Global Pharma
On February 25, 2026, pharmaceutical giant Eli Lilly officially...
EMA is Looking for a New Director. The Most Prestigious Vacancy in European Pharmaceuticals Has Opened
On February 20, 2026, the race for one of...
Top Ten Most Anticipated Drug Launches of 2026 That Will Reshape the Global Market
Experts from Evaluate forecast a record year for the...
An “AI Pill” for Indian Pharma: Sun Pharma and Glenmark Change the Rules of the Game
The Indian pharmaceutical industry, long known as the "pharmacy of the world" due to its generic drug production, is beginning a technological transformation.
Rospotrebnadzor Cleans Up the Web: 3,000 Resources with Dangerous Dietary Supplements Blocked
The Federal Service for Surveillance on Consumer Rights Protection...
Automated Fines for Expired Dietary Supplements to Start March 1 for Pharmacies
The dietary supplement (BAA) market will be the first...
EMA and PIC/S Tighten Control Over Active Pharmaceutical Substance Production
The European Medicines Agency (EMA), in collaboration with the...
What Happens in 2031? Regulator Sets “Deadline” for EAEU Veterinary Drug Rules
Since March 2024, supranational rules for the circulation of...
Transition to EAEU Standards: GMP Certification Rules for Veterinary Drugs are Changing
A draft Decree of the Government of the Russian...
Eli Lilly and Nvidia Launch LillyPod — The Most Powerful AI Supercomputer in Global Pharma
On February 25, 2026, pharmaceutical giant Eli Lilly officially...
An “AI Pill” for Indian Pharma: Sun Pharma and Glenmark Change the Rules of the Game
The Indian pharmaceutical industry, long known as the "pharmacy of the world" due to its generic drug production, is beginning a technological transformation.
SUSU Scientists Synthesize a Selective Anti-Anxiety Molecule
Researchers at South Ural State University (SUSU) have discovered...
Neural Network Breakthrough: FDA Approves Trials for AI-Created Parkinson’s Drug
January 23, 2026, became a landmark date for digital...
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
Production of the Russian Smallpox Drug “NIOCH-14” May Start in the Spring of 2026
This is the first chemical drug in Russia intended for the treatment and emergency prevention of smallpox and other orthopoxvirus infections, including mpox.
R-Pharm Import-Substitutes German Erbitux — Drug for Head and Neck Cancer Therapy
The Ministry of Health of the Russian Federation has...
Petrovax Pharm Investments in Meningitis Vaccine Production Exceed 3 Billion Rubles
Biopharmaceutical company Petrovax Pharm has announced receiving an expanded...
Ellara Prepares to Launch Unique Peptide Synthesis Facility
Pharmaceutical company Ellara is completing preparations for the opening...
GMP Registry: New Certificates Issued and Refusals in January 2026
On January 26, the Ministry of Industry and Trade...
EU Approves the Most Extensive Pharmaceutical Legislation Reform in 20 Years
The European Parliament and the Council of the European...
Eli Lilly and Nvidia Launch LillyPod — The Most Powerful AI Supercomputer in Global Pharma
On February 25, 2026, pharmaceutical giant Eli Lilly officially...
EMA is Looking for a New Director. The Most Prestigious Vacancy in European Pharmaceuticals Has Opened
On February 20, 2026, the race for one of...
Top Ten Most Anticipated Drug Launches of 2026 That Will Reshape the Global Market
Experts from Evaluate forecast a record year for the...
An “AI Pill” for Indian Pharma: Sun Pharma and Glenmark Change the Rules of the Game
The Indian pharmaceutical industry, long known as the "pharmacy of the world" due to its generic drug production, is beginning a technological transformation.
Rospotrebnadzor Cleans Up the Web: 3,000 Resources with Dangerous Dietary Supplements Blocked
The Federal Service for Surveillance on Consumer Rights Protection...
Automated Fines for Expired Dietary Supplements to Start March 1 for Pharmacies
The dietary supplement (BAA) market will be the first...
EMA and PIC/S Tighten Control Over Active Pharmaceutical Substance Production
The European Medicines Agency (EMA), in collaboration with the...
What Happens in 2031? Regulator Sets “Deadline” for EAEU Veterinary Drug Rules
Since March 2024, supranational rules for the circulation of...
Transition to EAEU Standards: GMP Certification Rules for Veterinary Drugs are Changing
A draft Decree of the Government of the Russian...
Eli Lilly and Nvidia Launch LillyPod — The Most Powerful AI Supercomputer in Global Pharma
On February 25, 2026, pharmaceutical giant Eli Lilly officially...
An “AI Pill” for Indian Pharma: Sun Pharma and Glenmark Change the Rules of the Game
The Indian pharmaceutical industry, long known as the "pharmacy of the world" due to its generic drug production, is beginning a technological transformation.
SUSU Scientists Synthesize a Selective Anti-Anxiety Molecule
Researchers at South Ural State University (SUSU) have discovered...
Neural Network Breakthrough: FDA Approves Trials for AI-Created Parkinson’s Drug
January 23, 2026, became a landmark date for digital...
Good AI Practice: EMA and FDA Establish 10 Global Principles
Global regulators are setting a unified standard for the...
PHARMPROM is a premier digital resource for the pharmaceutical sector, combining breaking news, deep insights, and key market events. We cover the entire product lifecycle—from R&D and manufacturing to distribution—in strict accordance with Good Pharmaceutical Practices (GxP).
Disclaimer All content on pharmprom.net is for informational purposes only and does not constitute medical advice. The materials are intended exclusively for industry professionals and are not addressed to the general public.
Headlines
A Line of Eight Probiotic-Based Edible Vaccines Developed in Russia
Scientists from the Institute of Experimental Medicine (IEM, St....
EBRD to Finance the Expansion of Pharmaceutical Production in Uzbekistan with €20 Million
The European Bank for Reconstruction and Development (EBRD) is...
Sale of 42 Million Unsafe Dietary Supplements Blocked. Ministry of Industry and Trade Strengthens Control
Ekaterina Priezzheva, Deputy Minister of Industry and Trade of...
EU Approves the Most Extensive Pharmaceutical Legislation Reform in 20 Years
The European Parliament and the Council of the European...
